Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non-Current Debt: 2021-2024

Historic Non-Current Debt for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Dec 2024 value amounting to $107.2 million.

  • Arcutis Biotherapeutics' Non-Current Debt rose 2.29% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 2.29%. This contributed to the annual value of $107.2 million for FY2024, which is 46.88% down from last year.
  • As of FY2024, Arcutis Biotherapeutics' Non-Current Debt stood at $107.2 million, which was down 46.88% from $201.8 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Non-Current Debt high stood at $201.8 million for FY2023, and its period low was $72.3 million during FY2021.
  • For the 3-year period, Arcutis Biotherapeutics' Non-Current Debt averaged around $168.9 million, with its median value being $197.8 million (2022).
  • In the last 5 years, Arcutis Biotherapeutics' Non-Current Debt surged by 173.35% in 2022 and then tumbled by 46.88% in 2024.
  • Arcutis Biotherapeutics' Non-Current Debt (Yearly) stood at $72.3 million in 2021, then skyrocketed by 173.35% to $197.8 million in 2022, then grew by 2.04% to $201.8 million in 2023, then crashed by 46.88% to $107.2 million in 2024.